Products for Research Use Only
RegisterLogin

NXT629

CAT: 0804-HY-114263-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114263-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively[1]. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models[2].
CAS Number
1454925-59-7
Product Name Alternative
(±)-Ibuprofen (L-lysine)
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NXT629.html
Concentration
10mM
Purity
99.07
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=CC=C1)(NC2=CC=C(C3=CC=C(CCCC(N4CC)=NN(CC5=CC=C(C(C)(C)C)C=C5)C4=O)C=C3)N=C2)=O
Molecular Formula
C35H39N5O3S
Molecular Weight
609.78
References & Citations
[1]Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24 (10) :2267-72.|[2]Stebbins KJ, et al. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. Eur J Pharmacol. 2017 Aug 15;809:130-140.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARα; PPARβ/δ; PPARγ

Related Products

CatalogName
HY-RS09721NXT2 Human Pre-designed siRNA Set A

Alternative Products

CatalogName
BA4436-5.1NXT629
A18771-5NXT629 5mg
A18771-100NXT629 100mg
A18771-25NXT629 25mg
A18771-50NXT629 50mg
A18771-2NXT629 2mg
A18771-10NXT629 10mg
A18771-1NXT629 1mg

Popular Products